Cemiplimab (Nurse)
Medication Basics
Drug Name
Cemiplimab (Brand names: Libtayo®)
Purpose / Indication
Used to treat certain cancers such as cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer, and other approved indications. Verify indication, regimen, line of therapy, biomarker requirements, and institutional protocol before administration.
Dosage & Administration
Dose Schedule
Commonly administered as an intravenous infusion every 3 weeks, though dosing and duration must follow the oncology provider’s treatment plan and current protocol.
Route
IV (Intravenous)
Timing Considerations
Confirm treatment plan, cycle timing, combination agents, hold parameters, infusion duration, and any required pre-infusion assessments before administration.
Time of Day
Flexible
Special Instructions
Assess baseline symptoms, review labs, confirm consent, educate on immune-related or targeted-therapy toxicities, and follow institutional hypersensitivity/infusion reaction procedures.
Injection Techniques
Administer by IV infusion per institutional policy and current prescribing information. Do not administer IV push or bolus unless specifically supported by policy.
Mechanism of Action
Mechanism
Cemiplimab is a PD-1 blocking monoclonal antibody that inhibits PD-1 interaction with PD-L1 and PD-L2, promoting immune-mediated antitumor activity.